PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsDulaglutide
Trulicity(dulaglutide)
Trulicity (dulaglutide) is a protein pharmaceutical. Dulaglutide was first approved as Trulicity on 2014-09-18. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
Trulicity (discontinued: Trulicity)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Dulaglutide
Tradename
Proper name
Company
Number
Date
Products
TrulicitydulaglutideEli LillyN-125469 RX2014-09-18
4 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
trulicityBiologic Licensing Application2025-07-03
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
A10: Drugs used in diabetes
A10B: Blood glucose lowering drugs, excl. insulins
A10BJ: Glucagon-like peptide-1 (glp-1) analogues
A10BJ05: Dulaglutide
HCPCS
No data
Clinical
Clinical Trials
125 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11201632151798
Diabetes mellitusD003920EFO_0000400E08-E1381418101161
ObesityD009765EFO_0001073E66.9639
Healthy volunteers/patients5117
OverweightD050177E66.31315
HyperglycemiaD006943R73.9134
Type 1 diabetes mellitusD003922EFO_0001359E10224
Fatty liverD005234EFO_0003934224
Kidney diseasesD007674EFO_0003086N081214
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.81123
Show 14 more
Indications Phases 3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FibrosisD00535511
Cystic fibrosisD003550EFO_0000390E8411
Exocrine pancreatic insufficiencyD010188K86.8111
Sexual arousalD00008394211
Body weight changesD00183611
Smoking cessationD016540EFO_000431911
CravingD06624911
Water-electrolyte imbalanceD01488311
ThirstD01389411
Psychogenic polydipsiaD05960711
Indications Phases 1
No data
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart disease risk factorsD00008274222
CarcinomaD002277C80.011
Thyroid neoplasmsD013964EFO_000384111
Neuroendocrine carcinomaD01827811
Papillary thyroid cancerD00007727311
Thyroid diseasesD013959E00-E0711
Pediatric obesityD06376611
Retinal diseasesD012164H35.911
Mental disordersD001523EFO_0000677F91.911
Bipolar disorderD001714EFO_0000289F30.911
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDulaglutide
INNdulaglutide
Description
Dulaglutide, sold under the brand name Trulicity among others, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. It is a once-weekly injection.
Classification
Protein
Drug classpeptides: glucagon-like peptide (GLP) analogs
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL2108027
ChEBI ID
PubChem CID
DrugBankDB09045
UNII IDWTT295HSY5 (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
£
Trulicity Eli Lilly
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Dulaglutide
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 5,360 documents
View more details
Safety
Black-box Warning
Black-box warning for: Trulicity
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
73,057 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use